New Insights on Givinostat for Duchenne Muscular Dystrophy Highlighted at 2026 MDA Conference ITF Therapeutics has unveiled significant findings regarding Givinostat for Duchenne Muscular Dystrophy at the 2026 MDA Conference, focusing on safety and efficacy.

New Insights on Givinostat for Duchenne Muscular Dystrophy Highlighted at 2026 MDA Conference #United_States #ITF_Therapeutics #Concord #Duchenne_Muscular_Dystrophy #givinostat

ITF Therapeutics Unveils Promising Findings at 2026 MDA Clinic Conference ITF Therapeutics LLC shares significant data on givinostat for Duchenne muscular dystrophy at the 2026 MDA Clinical Conference. Learn about their presentations.

ITF Therapeutics Unveils Promising Findings at 2026 MDA Clinic Conference #USA #Orlando #ITF_Therapeutics #DUVYZAT #givinostat

New Insights on Givinostat's Efficacy for Duchenne Muscular Dystrophy Unveiled at NMSG Meeting 2025 Recent findings on givinostat's use for treating Duchenne muscular dystrophy were presented at the 2025 NMSG Annual Scientific Meeting in Italy, focusing on flexible dosing and outcomes.

New Insights on Givinostat's Efficacy for Duchenne Muscular Dystrophy Unveiled at NMSG Meeting 2025 #United_States #Massachusetts #ITF_Therapeutics #DMD #givinostat

ITF Therapeutics Opens New Headquarters in Concord to Enhance Rare Disease Solutions ITF Therapeutics has opened a new headquarters in Concord, Massachusetts, focusing on rare diseases and community engagement. Aimed at fostering collaboration, it will serve as a hub for patient advocacy.

ITF Therapeutics Opens New Headquarters in Concord to Enhance Rare Disease Solutions #USA #ITF_Therapeutics #DUVYZAT #Concord #Italfarmaco

ITF Therapeutics to Present Groundbreaking Findings at MDA 2025 Conference in Dallas ITF Therapeutics LLC announces acceptance of seven abstracts for poster presentations at the 2025 MDA Conference showcasing DUVYZAT’s impact on DMD patients.

ITF Therapeutics to Present Groundbreaking Findings at MDA 2025 Conference in Dallas #USA #Dallas #ITF_Therapeutics #DUVYZAT #Duchenne

Like they paid our cost! So we would hit our max out of pocket. So the rest of the year insurance covers everything.

And we owe nothing.

This is the best present right now. I have no words. Just a lot of tears. The manufacturer of this drug is #ITF_therapeutics & the drug is #givinostat #duvyzat

ITF Therapeutics Welcomes Erica L. Monaco as New COO to Lead Operational Efforts ITF Therapeutics LLC has appointed Erica L. Monaco as its new Chief Operating Officer, bringing a wealth of experience in the pharmaceutical and financial industries.

ITF Therapeutics Welcomes Erica L. Monaco as New COO to Lead Operational Efforts #USA #ITF_Therapeutics #Erica_Monaco #DUVYZAT #Concord